DDInter899 DDInter424
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cobicistat may lead to a major life threatening interaction when taken with Methylprednisolone
Cobicistat may lead to a major life threatening interaction when taken with Berotralstat